CD274 and triple-negative breast carcinoma: Atezolizumab, a human PD-L1-specific antibody approved to treat urothelial cancer and triple-negative breast cancer, is one of three commercially available PD-L1 monoclonal antibodies, along with Avelumab and Durvalumab [6,9,21–24].